WYZGA MICHAEL S 4

What Happened
Michael S. Wyzga, a director of Tvardi Therapeutics, was granted a derivative award covering 6,000 shares on June 9, 2026. The filing shows an acquisition at $0.00 (no cash paid at grant). This is an award/compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-09; reported on Form 4 filed 2026-06-11 (timely filing).
• Type: Grant / award of a derivative instrument covering 6,000 shares (transaction code A). Reported acquisition price: $0.00.
• Shares owned after transaction: Not specified in the Form 4 filing.
• Vesting: Per the filing footnote, 100% of the shares underlying the award vest on the earlier of June 9, 2027 or the issuer’s next annual meeting of stockholders, subject to continuous service.
• No immediate sale or cash exercise reported.

Context: This appears to be a standard director compensation award (option/RSU-style derivative) with a one-year or event-based vesting condition. Such grants are common and do not by themselves signal an insider buying or selling stock; they represent future potential ownership contingent on continued service and vesting.